Britain’s Clinigen Group Plc has agreed to a sweetened takeover offer by UK-based private equity firm Triton, valuing the pharmaceutical services firm at about $1.78bn.
Shareholders in Clinigen, whose top investor is hedge fund Elliott, will receive 925 pence per share in cash, up from a December bid of 883 pence apiece.
Get the week’s top news delivered directly to your inbox – Sign up for our newsletter
New York-based Elliott, which had been raising its holding in Clinigen over the past few months amid reports it was seeking a break-up of the group, owns a 10.5% stake in the British company, according to Refintiv Eikon data.
The latest offer by Triley Bidco, a newly created company indirectly owned by Triton Funds, is final and is recommended by the Clinigen board, the companies said in a joint statement.
Triton’s first offer made in December valued Clinigen, which provides healthcare professionals and their patients with access to medicines, at about 1.2 billion pounds.
Source: FX Empire
Can’t stop reading? Read more
Oscar-winning Lion Forge secures $30m from HarbourView to expand IP portfolio
Oscar-winning Lion Forge secures $30m from HarbourView to expand IP portfolio HarbourView Equity...
Klarna set to price IPO above range as demand surges for $1.27bn listing
Klarna set to price IPO above range as demand surges for $1.27bn listing Klarna is preparing to...
Dragon’s Den star Touker Suleyman bids to rescue Claire’s UK stores
Dragon’s Den star Touker Suleyman bids to rescue Claire’s UK stores Touker Suleyman, investor and...